Cytokines in the Pathophysiology of Systemic Lupus Erythematosus

References

• Gleichmann E, Pals S T, Rolink A G, Radaskiewicz T, Gleichmann H. Graft-versus-host reactions: clues to the etiology of a spectrum of immunological diseases. Immunol Today 1984; 5: 324–332
   PubMedGoogle Scholar
• Smith H R, Steinberg A D. Autoimmunity. A perspective. Ann Rev Immunol 1983; 1: 175–210
   PubMed Web of Science ®Google Scholar
• Theofilopoulos A N, Dixon F J. Murine models of systemic lupus erythematosus. Adv Immunol 1985; 37: 269–390
   PubMed Web of Science ®Google Scholar
• Goldman M, Baran D, Druet P. Polyclonal activation and experimental nephropathies. Kidney Iit 1988; 34: 141–150
   PubMed Web of Science ®Google Scholar
• Prud' homme G J, Palfrey N A. Biology of disease: role of T helper lymphocytes in autoimmune diseases. Lab Invest 1988; 59: 158–172
   PubMedGoogle Scholar
• Kelso A. Cytokines: structure, function and synthesis. Current Opinion Immunol 1989; 2: 215–225
   PubMed Web of Science ®Google Scholar
• Andrews B S, Eisenberg R A, Theofilopoulos A N, Izui S, Wilson C B, McConahey P J, Murphy E D, Roths J B., Dixon F J. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med 1978; 148: 1198–1215
   PubMed Web of Science ®Google Scholar
• Izui S, McConahey P J, Dixon F J. Increased spontaneous polyclonal activation of B lymphocytes in mice with spontaneous autoimmune disease. J Immunol 1978; 121: 2213–219
   PubMed Web of Science ®Google Scholar
• Theofilopoulos A N, Shawler D L, Eisenberg R A, Dixon F J. Splenic immunoglobin secreting cells and their regulation in autoimmune mice. J Exp Med 1980; 158: 446–466
   Google Scholar
• Kincade P W, Lee G, Fernandes G, Moore M A, Williams N, Good R A. Abnormalities in clonable B lymphocytes and myeloid progenitors in autoimmune NZB mice. Proc Natl Acad Sci USA 1979; 76: 3464–3468
   PubMed Web of Science ®Google Scholar
• Jasin H E, Ziff M. Immunoglobin synthesis by peripheral blood cells in systemic lupus erythematosus. Arthritis Rheum 1975; 18: 219–228
   PubMed Web of Science ®Google Scholar
• Nies K M, Louie J S. Impaired immunoglobulin synthesis by peripheral blood lymphocytes in systemic lupus erythematosus. Arthritis Rheum 1978; 21: 51–57
   PubMedGoogle Scholar
• Ginsburg W W., Finkelman F D, Lipsky P E. Circulating and pokeweed mitogen-induced immunoglobulin-secreting cells in systemic lupus erythematosus. Clin Exp Immunol 1979; 35: 76–88
   PubMed Web of Science ®Google Scholar
• Blaese R M, Grayson J, Steinberg A D. Elevated immunoglobulin secreting cells in the blood of patients with actove systemic lupus erythematosus.: correlation of laboratory and clinical assessment of disease activity. Am J Med 1980; 69: 345–350
   PubMed Web of Science ®Google Scholar
• Kumagai S, Sredni B, House S, Steinberg A D, Green I. Defective regulation of B lymphocyte colony formation in patients with systemic lupus erythematosus. J Immunol 1982; 128: 258–262
   PubMedGoogle Scholar
• Prud'homme G J, Balderas R S, Dixon F J, Theofilopoulos A N. B cell dependence on and response to accessory signals in murine lupus strains. J Exp Med 1983; 157: 1815–1827
   PubMedGoogle Scholar
• Herron L R, Coffman R L, Kotzin B L. Enhanced response of autoantibody-secreting B cells from young NZB/NZW mice to T cell-derived differentation signals. Clin Immunol Immunopathol 1988; 46: 314–327
   PubMedGoogle Scholar
• Umland S P, Fei N Go, Howard M. Responses of B cells from autoimmune mice to IL-5. J Immunol 1989; 142: 1528–1535
   PubMed Web of Science ®Google Scholar
• Gutierrez C, Howard M, Gaspar M L, Raveche E S. Differential proliferative responses of B cells from Balb/c and autoimmune NZB mice to B-cell growth factor(s). Clin Immunol Immunopathol 1986; 39: 319–328
   PubMedGoogle Scholar
• Ando D G, Sercarez E E, Hahn B H. Mechanisms of T and B cell collaboration in the in vitro production of anti-DNA antibodies in the NZB/NZW F1 murine SLE model. J Immunol 1987; 138: 3185–3190
   PubMed Web of Science ®Google Scholar
• Datta S K, Patel H, Berry D. Induction of a cationic shift in IgG anti-DNA antibodies. Role of T helper cells with classical and novel phenotypes in three murine models of lupus nephritis. J Exp Med 1987; 165: 1252–1268
   PubMed Web of Science ®Google Scholar
• Klinman D S, Steinberg A D. Systemic autoimmune disease arises from polyclonal B cell activation. J Exp Med 1987; 165: 1755–1760
   PubMed Web of Science ®Google Scholar
• Fournie G J. Circulating DNA and lupus nephritis. Kidney Int 1988; 33: 487–497
   PubMedGoogle Scholar
• Hayakawa K, Hardy R R, Honda M, Herzenberg L A, Steinberg A D, Herzenberg L A. Ly-1 B cells: functionally distinct lymphocytes that secrete IgM autoantibodies. Proc Natl Acad Sci USA 1984; 81: 2494–2498
   PubMed Web of Science ®Google Scholar
• Prud'homme G J, Park C L, Fieser T M, Kofler R, Dixon F J, Theofilopoulos A N. Identification of a B cell differentation factor(s) spontaneously produced by proliferating T cells in murine lupus strains of the 1 pr/1 pr genotype. J Exp Med 1983; 157: 730–742
   PubMed Web of Science ®Google Scholar
• Rosenberg Y J, Goldsmith P K, Ohara J, Steinberg A D, Ohriner W. la antigen expression and autoimmunity in MRL-Ipr/lpr mice. Ann NY Acad Sci 1986; 475: 251–265
   PubMedGoogle Scholar
• Dobashi K, Ono S, Murakami S, Takahama Y, Katoh Y, Hamaoka T. Polyclonal B cell activation by a B cell differentiation factor, B151-TRF2. III. B151-TRF2 as a B cell differentiation factor closely associated with autoimmune disease. J Immunol 1987; 138: 780–787
   PubMedGoogle Scholar
• Kishimoto T, Hirano T. Molecular regulation of B lymphocyte response. Ann Rev Immunol 1988; 6: 485–512
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Saito K, Shirakawa F, Ota T, Suzuki H, Eto S, Yamashita U. Production of B cell-stimulating factors by B cells in patients with systemic lupus erythematosus. J Immunol 1988; 141: 3043–3049
   PubMed Web of Science ®Google Scholar
• Kitani A, Hara M, Hirose T, Norioka K, Harigai M, Hirose W, Suzuki K, Kawakami M, Kawagoe M, Nakamura H. Heterogeneity of B cell responsiveness to interleukin 4, inter-leukin-6 and low molecular weight B cell growth factor in discrete stages of B cell activation in patients with systemic lupus erythematosus. Clin Exp Immunol 1989; 77: 31–36
   PubMedGoogle Scholar
• Rosenberg Y J, Steinberg A D, Santoro T J. T cells from autoimmune IL2 defective MRL-lpr/lpr mice continue to grow in vitro and produce 1L2 constitutively. J Immunol 1984; 133: 2545–2548
   PubMedGoogle Scholar
• Lu C Y, Unanue E R. Spontaneous T cell lymphokine production and enhanced macrophage la expression and tum-oricidal activity in MRL-lpr/lpr mice. Clin Immunol Immunopathol 1982; 25: 213–22
   PubMedGoogle Scholar
• Manolois N, Schreiber L, Nelson M, Geczy C L. Enhanced interferon-gamma production by lymph node cells from autoimmune (MRL/1, MRL/n) mice. Clin Exp Immunol 1989; 76: 301–306
   PubMedGoogle Scholar
• Leibson H J, Gefter M, Zlotnik A, Marrack P, Kappler J W. Role of gamma-interferon in antibody-producing responses. Nature 1984; 309: 799–802
   PubMed Web of Science ®Google Scholar
• Sidman C L, Marshall J D, Shulz L D, Gray P W, Johnson H M. Gamma-interferon is one of several B cell-maturing lymphokines. Nature 1984; 309: 801–803
   PubMed Web of Science ®Google Scholar
• Santoro T J, Benjamin W R, Oppenheim J J, Steinberg A D. The cellular basis for immune interferon production in autoimmune MRL-lpr/lpr mice. J Immunol 1983; 131: 265–268
   PubMedGoogle Scholar
• Heremans S, Billiau A, Colombatti A, Hilgers J, De Somer P. Interferon treatment of NZB mice: accelerated progression of autoimmune disease. Infect Immunol 1978; 21: 925–930
   PubMed Web of Science ®Google Scholar
• Adam C, Thoua Y, Ronco P, Verroust P, Tovey M, Morel-Moroger L. The effect of exogenous interferon: acceleration of autoimmune and renal diseases in (NZB/W)F1 mice. Clin Exp Immunmol 1980; 40: 373–382
   PubMed Web of Science ®Google Scholar
• Engleman E G., Sonnenfeld G, Dauphinee M, Greenspan J S, Talal N, McDevitt H O, Merigan T C. Treatment of NZW Fl mice with mycobacterium bovis strain BCG or type II interferon preparations accelerates autoimmune disease. Arthritis Rheum 1981; 24: 1396–1402
   PubMed Web of Science ®Google Scholar
• Seitz M, Franke M, Kirchner H. Induction of antinuclear antibodies in patients receiving treatment with human recombinant interferon gamma. Ann Rheum Dis 1898; 47: 642–644
   Google Scholar
• Hooks J J, Moutsopoulos H M, Geis S A, Stahl N I, Decker J L, Notkins A L. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979; 301: 5–10
   PubMed Web of Science ®Google Scholar
• Preble O T, Black R J, Friedman R M, Klippel J H, Vilcek J. Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science 1982; 216: 429–431
   PubMed Web of Science ®Google Scholar
• Rich S A. Human lupus inclusions and interferon. Science 1981; 213: 772–775
   PubMed Web of Science ®Google Scholar
• Schattner A. Review: interferons and autoimmunity. Am J Med Sci 1988; 195: 532–544
   Google Scholar
• Eyster M E, Goedert J J, Poon M C, Preble O T. Acid-labile alpha interferon: a possible preclinical marker for the acquired immunodeficiency syndrome in hemophilia. N Engl J Med 1983; 309: 583–586
   PubMed Web of Science ®Google Scholar
• Kopelman R G, Zolla-Paznzer S. Association of human immunodeficiency virus infection and autoimmune phenomena. Am J Med 1988; 84: 82–88
   PubMed Web of Science ®Google Scholar
• Pincus T. Studies regarding a possible function of viruses in the pathogenesis of systemic lupus eythematosus. Arthritis Rheum 1982; 25: 847–856
   PubMedGoogle Scholar
• Morse H C, Davidson W F, Yetter R A, Murphy E, Roths J B, Coffman R L. Abnormalities induced by the mutant gene lpr: expansion of a unique lymphocyte subset. J Immunol 1982; 129: 2612–2615
   PubMed Web of Science ®Google Scholar
• Santoro T J, Portnova J P, Kotzin B L. The contribution of L3T4+ cells to lymphoproliferation and autoantibody production in MRL-lpr/lpr mice. J Exp Med 1988; 167: 1713–1719
   PubMedGoogle Scholar
• Kelley V E, Roths J B. Increase in macrophage la expression in autoimmune mice: role of the lpr gene. J Immunol 1982; 129: 923–925
   PubMedGoogle Scholar
• Rosenberg Y J, Steinberg A D, Santoro T J. The basis of autoimmunity in MRL-lpr/lpr mice: a role for self la-reactive T cells. Immunol Today 1984; 5: 64–67
   PubMedGoogle Scholar
• Volk H D, Kopp J, Korner J, Jahn S, Grunow R, Barthelmes H, Fiebig H. Correlation between the phenotype and the functional capacity of activated T cells in patients with active systemic lupus erythematosus. Scand J Immunol 1986; 24: 109–114
   PubMedGoogle Scholar
• Huang Y P, Perrin L H, Miescher P A, Zubler R H. Correlation of T and B cell activities in vitro and serum IL-2 levels in systemic lupus erythematosus. J Immunol 1988; 141: 827–833
   PubMed Web of Science ®Google Scholar
• Rolink A G, Pals S T, Gleichmann E. Allosuppressor an allohelper T cells in acute and chronic graft-versus-host disease. II. Fl recipients carrying mutations at H-2K and/or I-A. J Exp Med 1983; 157: 755–771
   PubMed Web of Science ®Google Scholar
• Rolink A G, Pals S T, Gleichmann E. Allosuppressor and allohelper T cells in acute and chronic graft-versus-host disease. III. Different Lyt subsets of donor T cells induce different pathological syndromes. J Exp Med 1983; 158: 546–558
   PubMedGoogle Scholar
• Via C S, Shearer G M. T cell interactions in autoimmunity: insights from a murine model of graft-versus-host disease. Immunol Today 1988; 9: 207–213
   PubMedGoogle Scholar
• Gleichmann E, Van Elven E H, Van Der Veen J P. A systemic lupus erythematosus (SLE)-like disease in mice induced by abnormal T-B cell cooperation. Preferential formation of autoantibodies characteristic of SLE. Eur J Immunol 1982; 12: 152–159
   PubMed Web of Science ®Google Scholar
• Lewis R M, Armstrong M Y, Andre-Schwartz J, Muftuoglu A, Beldotti L, Schwartz R S. Chronic allogenic disease. I. Development of glomerulonephritis. J Exp Med 1968; 128: 653–679
   PubMed Web of Science ®Google Scholar
• Bruijn J A, Van Elven E H, Hogendoorn P CW, Corver W E, Hoedemaeker P J, Fleuren G J. Murine chronic graft-versus-host disease as a model for lupus mephritis. Am J Pathol 1988; 130: 639–641
   PubMed Web of Science ®Google Scholar
• Doutrelepont J M, Moser M, Leo O, Abramowicz D, Vander-Haeghen M L, Urbain J, Goldman M. HyperlgE in stimulatory graft-versus-host disease: role of interleukin-4. Clin Exp Immunol 1990, in press
   Google Scholar
• Hard R C, Kullgren B. Etiology, pathogenesis and prevention of a fatal host-versus-graft syndrome in parent/Fl mouse chimeras. Am J Pathol 1970; 59: 203–224
   PubMedGoogle Scholar
• Goldman M, Feng H M, Engers H, Hochmann A, Louis J, Lambert P H. Autoimmunity and immune complex disease after neonatal induction of transplatation tolerance in mice. J Immunol 1983; 131: 251–258
   PubMedGoogle Scholar
• Billingham R W, Brent L. Quantitative studies on tissue transplantation immunity. IV. Induction of tolerance in newborn mice and studies on the phenomenon of runt disease. Philos Trans R Soc Lond (Bio Sci) 1969; 242: 439–477
   Google Scholar
• Brent L, Brooks C G, Medawar P B, Simpson E. Transplantation tolerance. Br Med Bull 1976; 32: 101–106
   PubMed Web of Science ®Google Scholar
• Feng H M, Glasebrook A L, Engers H D, Louis J A. Clonal analysis of T cell unresponsiveness to alloantigens induced by neonatal injection of Fl spleen cells into parental mice. J Immunol 1983; 131: 2165–2169
   PubMedGoogle Scholar
• Silobrcic V. Life-long tolerance and chimerism in parental mice induced with Fl hybrid cells. Eur J Immunol 1971; 1: 313–315
   PubMedGoogle Scholar
• Luzuy S, Merino J, Engers H, Izui S, Lambert P H. Autoimmunity after induction of neonatal tolerance to alloantigens: role of B cell chimerism sand Fl donor B cell activation. J Immunol 1986; 136: 4420–4426
   PubMedGoogle Scholar
• Goldman M, Abramowicz D, Lambert P, Van Der Vorst P., Bruyns C, Toussaint C. Hyperactivity of donor B cells after neonatal induction of lymphoid chimerism in mice. Clin Exp Immunol 1988; 72: 79–83
   PubMedGoogle Scholar
• Abramowicz D, Doutrelepont J M, Lambert P, Van Der Vorst P, Bruyns C, Goldman M. Increased expression of la antigens on B cells after neonatal induction of lymphoid chimerism in mice: role of interleukin 4. Eur J Immunol 1990
   Google Scholar
• Goldman M, Van Der Vorst P., Lambert P, Doutrelepont J M, Bruyns C, Abramowicz D. Persistence of allohelper T cells secreting interleukin-4 after neonatal induction of transplantation tolerance. Transplant Proc 1989, à complet.
   Google Scholar
• Merino J, Schurmans S, Luzuy S, Izui S, Vassalli, Lambert P H. Autoimmune syndrome after induction of neonatal tolerance to alloantigens. Effects of in vivo treatment with anti-T cell subset monoclonal antibodies. J Immunol 1987; 139: 1426–1431
   PubMedGoogle Scholar
• Merino J, Schurmans S, Duchosal M A, Izui S, Lambert P H. Autoimmune syndrome after induction of neonatal tolerance to alloantigens. CD4+ T cells from the tolerant host activate autoreactive Fl B cells. J Immunol 1989; 143: 2202–2208
   PubMed Web of Science ®Google Scholar
• Mosmann T R, Coffman R L. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol 1989; 46: 111–147
   PubMed Web of Science ®Google Scholar
• Altman A, Theofilopoulos A N, Weiner R, Katz D H, Dixon F J. Analysis of T cell function in autoimmune murine strains. Defects in production of and responsiveness to interleukin-2. J Exp Med 1981; 154: 791–808
   PubMed Web of Science ®Google Scholar
• Dauphinee M J, Kipper S B, Wofsy D, Talal N. Interleukin 2 deficiency is a common feature of autoimmune mice. J Immunol 1981; 127: 2483–2487
   PubMed Web of Science ®Google Scholar
• Wofsy D, Murphy E D, Roths J B, Dauphinee M J, Kipper S B, Talal N. Deficient interleukin 2 activity in MRL/1 and C57B1/ 6J mice bearing the lpr gene. J Exp Med 1981; 154: 1671–1679
   PubMed Web of Science ®Google Scholar
• Alcoger-Varela J, Alarcon-Segovia D. Decreased production of and response to interleukin 2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 1982; 69: 1388–1392
   PubMedGoogle Scholar
• Murakawa Y, Takada S, Ueda Y, Suzuki N, Hoshino T, Sakane T. Characterization of T lymphocyte subpopulations responsible for deficient interleukin 2 activity in patients with systemic lupus erythematosus. J Immunol 1985; 134: 187–195
   PubMed Web of Science ®Google Scholar
• Wofsy D, Seaman E. Successful treatment of autoimmunity in NZB/W Fl mice with monoclonal antibody to L3T4. J Exp Med 1985; 161: 378–391
   PubMed Web of Science ®Google Scholar
• Reimann J, Diamanstein T. Interleukin-2 allows in vivo induction of anti-erythrocyte autoantibody production in nude mice in association with the injection of rat erythrocytes. Clin Ex Immunol 1981; 43: 641–644
   PubMedGoogle Scholar
• Krömer G, Wick G. The role of interleukin 2 in autoimmunity. Immunol Today 1989; 10: 246–251
   PubMedGoogle Scholar
• Moser M, Mizouchi T, Sharrow S O, Singer A S, Shearer G M. Graft-vs-host reaction limited to a class II MHC difference results in a selective deficiency in L3T4 but no in Lyt-2 helper T cell function. J Immunol 1987; 138: 1355–1364
   PubMed Web of Science ®Google Scholar
• Via C S, Shearer G M. Functional heterogeneity of L3T4 + cells in MRL-lpr/lpr mice. L3T4+ cells suppress major histocompatibility comples-self-restricted L3T4+ T helper cell function in association with autoimmunity. J Exp Med 1988; 168: 2165–2181
   PubMed Web of Science ®Google Scholar
• Huang Y P, Miescher P A, Zubler R H. The interleukin 2 secretion defect in vitro in systemic lupus erythematosus is reversible in rested cultured cells. J Immunol 1986; 137: 3515–3520
   PubMed Web of Science ®Google Scholar
• Wofsy D. Treatment of autoimmune diseases with monoclonal antibodies. Monoclonal antibody therapy, H Waldmann. Prog Allergy, Basel, Karger 1988; 45: 106–120
   Google Scholar
• Taniguchi T. Regulation of cytokine gene expression. Ann Rev Immunol 1988; 6: 439–464
   PubMed Web of Science ®Google Scholar
• Jacob C D, van der Meicle P H, Mc Devitt H O. In vivo treatment of (NZBxNZW)F1 lupus-like nephritis with monoclonal antibody to gamma-interferon. J Exp Med 1987; 166: 798–803
   PubMed Web of Science ®Google Scholar
• Kelley V E, Gaulton G N, Hattori M, Ikegami H, Eisenbarth G, Strom T B. Anti-interleukin 2 receptor antibody suppresses murine diabetic insulitis and lupus nephritis. J Immunol 1988; 140: 59–61
   PubMedGoogle Scholar
• Snyder D S, Beller D I, Unanue E R. Prostaglandins modulate macrophage la expression. Nature 1982; 299: 163–165
   PubMed Web of Science ®Google Scholar
• Kelley V E, Winkelstein A, Izui S, Dixon F J. Prostaglandin E1 inhibits T-cell proliferation and renal disease in MRL/1 mice. Clin Immunol Immunopathol 1981; 21: 190–195
   PubMedGoogle Scholar
• Nagayama Y, Namura Y, Tamura T, Muso R. Beneficial effect of prostaglandin E1 in three cases of lupus nephritis with nephrotic syndrome. Ann Allergy 1988; 61: 289–295
   PubMedGoogle Scholar
• Adelman N E, Watling D L, McDevitt H O. Treatment of (NZBxNZW)F1 disease with anti-I-A monoclonal antibodies. J Exp Med 1983; 158: 1350–1355
   PubMed Web of Science ®Google Scholar
• Jacob C O, McDevitt H O. Tumor necrosis factor-alpha in murine autoimmune lupus nephritis. Nature 1988; 331: 356–358
   PubMed Web of Science ®Google Scholar
• Gordon C, Ranges G E, Greespan J S, Wofsy D. Chronic therapy with recombinant tumor necrosis factor in autoimmune NZB/NZW Fl mice. Clin Immunol Immunopathol 1989; 52: 421–434
   PubMedGoogle Scholar